rezpegaldesleukin

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.

Nektar Therapeutics ($NKTR) faces class action lawsuit alleging false statements about REZOLVE-AA trial protocol adherence, threatening regulatory approval timelines and shareholder value.

Schall Law Firm seeks investors in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment and integrity.